Skip to main content
69°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
86.66
+0.77 (+0.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
56
57
Next >
AstraZeneca's COVID-19 Antibody Treatment Scores Approval In Europe
September 20, 2022
Via
Benzinga
Danicopan (ALXN2040) Add-On to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis
September 16, 2022
From
Alexion
Via
Business Wire
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
September 16, 2022
Via
Benzinga
AstraZeneca's Blood Clot Treatment Hits Primary Goal In Rare Blood Disorder Trial
September 16, 2022
Via
Benzinga
AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
September 15, 2022
From
AstraZeneca
Via
Business Wire
Top Financial Stories Tuesday, September 13: Elon Musk's Takeover Set To Get Twitter Shareholder Approval, Intel Slashes Mobileye IPO Valuation, Goldman Sachs To Layoff About 500 Jobs And More...
September 13, 2022
Wall Street Journal
Via
Benzinga
US Judge Dismisses Shareholder Lawsuit Over AstraZeneca's COVID-19 Vaccine Disclosures: Report
September 13, 2022
Via
Benzinga
IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
September 12, 2022
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
September 11, 2022
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
September 11, 2022
From
AstraZeneca
Via
Business Wire
TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
September 11, 2022
From
AstraZeneca
Via
Business Wire
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
September 09, 2022
Via
Benzinga
AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer
September 09, 2022
Via
Benzinga
LYNPARZA® (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials
September 09, 2022
From
AstraZeneca
Via
Business Wire
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
September 06, 2022
Via
Benzinga
AstraZeneca Imfinzi Combo Scores FDA Approval As First Immunotherapy Regimen For Biliary Tract Cancer
September 06, 2022
Via
Benzinga
IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
September 05, 2022
From
AstraZeneca
Via
Business Wire
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
September 02, 2022
Via
Benzinga
Here's How Much $1000 Invested In AstraZeneca 5 Years Ago Would Be Worth Today
September 01, 2022
AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 5.5% on an annualized basis producing an average annual return of 15.24%. Currently, AstraZeneca has a market...
Via
Benzinga
AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment
August 30, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
August 29, 2022
Upgrades
Via
Benzinga
Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial
August 29, 2022
Via
Benzinga
AstraZeneca Touts Positive Farxiga Data, Seeks Label Expansion In Heart Failure
August 29, 2022
AstraZeneca Plc (NASDAQ: AZN) laid out the details of the Farxiga's performance in another heart failure patient population at the European Society of Cardiology Congress.
Via
Benzinga
Week In Review: China And The US May Settle De-Listing/Accounting Impasse
August 27, 2022
China and the US are close to solving the accounting rules crisis that threatens to de-list 261 China companies from US exchanges. The list of affected biopharma companies includes BeiGene, Legend Bio,...
Via
Talk Markets
New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
August 27, 2022
From
AstraZeneca
Via
Business Wire
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
August 27, 2022
From
AstraZeneca
Via
Business Wire
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 25, 2022
Via
Benzinga
Back-To-Back Three Japanese Approvals For AstraZeneca's Rare Disease Treatments
August 25, 2022
Via
Benzinga
AstraZeneca's CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions
August 24, 2022
In a Reuters report, AstraZeneca Plc's (NASDAQ:
Via
Benzinga
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
August 24, 2022
From
AstraZeneca
Via
Business Wire
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
56
57
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.